Functional Concept
Surrozen sets its sights on ophthalmology after binning liver programme
Ophthalmology specialty, Severe (severity modifier)
Future in doubt as Opthea’s AMD drug flunks first pivotal study
Opthea ‘s, Opthea, Future, Clinical Research
23andMe files for bankruptcy as CEO Anne Wojcicki steps down to become bidder
Bankruptcy, CEO, Anne, Customer
Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks
Novo Nordisk, UBT251, obesity treatment, triple agonist, weight loss, GLP-1, GIP, glucagon, The United Laboratories International Holdings Limited
Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking the big next step after AlphaFold 3
Neo-1, Study models, molecular glues
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Fabhalta, United States Food and Drug Administration, Apellis, Novartis, Approved, C3 G, Proteinuria, pegcetacoplan, Kidney Diseases
MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results
MacroGenics, vobra duo, antibody-drug conjugate, B7-H3, prostate cancer, TAMARACK trial, discontinued development, safety concerns
Drugmakers renew concerns over UK’s attractiveness for investment
Investments, UK, UK ‘s, concerns, Industry, attractiveness
Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics
OBT, therapeutic autologous dendritic cells, Roche (company), Partnership, Oxford BioTherapeutics, Antibody-Drug Conjugates, biobucks, New
Dexcom survey shows healthcare providers opt for CGM tech over new medications in Type 2 diabetes
Continuous Glucose Monitoring System, Technology, Health Personnel, CGM, Diabetes Mellitus, Non-Insulin-Dependent